Hemopoietic cell transplantation for patients with myelodysplastic syndrome (MDS).*
| . | Outcome (%) at 3 Years . | ||
|---|---|---|---|
| MDS Risk Group . | Relapse . | NRM . | RFS . |
| Abbreviations: NRM, non-relapse mortality; RFS, relapse-free survival; IPSS, International Prognostic Scoring System. | |||
| *Reprinted with permission from Deeg HJ, Storer B, Slattery JT, et al. .7 Blood . 2002 ;100 :1201 –1207 | |||
| All patients (n = 109) | 13 | 31 | 57 |
| IPSS – low | 0 | 20 | 80 |
| – intermediate-1 | 6 | 30 | 64 |
| – intermediate-2 | 29 | 31 | 40 |
| – high | 42 | 29 | 29 |
| . | Outcome (%) at 3 Years . | ||
|---|---|---|---|
| MDS Risk Group . | Relapse . | NRM . | RFS . |
| Abbreviations: NRM, non-relapse mortality; RFS, relapse-free survival; IPSS, International Prognostic Scoring System. | |||
| *Reprinted with permission from Deeg HJ, Storer B, Slattery JT, et al. .7 Blood . 2002 ;100 :1201 –1207 | |||
| All patients (n = 109) | 13 | 31 | 57 |
| IPSS – low | 0 | 20 | 80 |
| – intermediate-1 | 6 | 30 | 64 |
| – intermediate-2 | 29 | 31 | 40 |
| – high | 42 | 29 | 29 |